Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patients

Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patients

Immune checkpoint inhibitors (ICIs) are first line treatment for advanced lung cancer. Tobacco use is a shared risk factor for lung cancer and chronic obstructive pulmonary disease (COPD). Although many patients with COPD and lung cancer receive ICIs, the impact of ICIs on COPD is unknown. Here, we...

Full description

Saved in:
Bibliographic Details
Main Authors: Anet Greib, Songzhu Zhao, Michelle Ploch, Jonathan Henricks, Robert Easterling, Meghana Moodabagil, Gabrielle Lopez, Mingjia Li, Evelyn G. Goodyear, John Sharp, Asrar Alahmadi, Jacob Kaufman, Regan Memmott, Kai He, Peter Shields, David P. Carbone, Gregory A. Otterson, Carolyn J. Presley, Lai Wei, Dwight H. Owen, Kevin Ho
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:OncoImmunology
Subjects:
Chronic obstructive pulmonary disease (COPD)
immune checkpoint inhibitors (ICI)
lung cancer
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2025.2469375
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2025.2469375

Similar Items